Nautilus Biotechnology, Inc. (NAUT)

US — Healthcare Sector
Peers: CCCC  KYMR  FHTX  RVMD  IPSC  BCAB  PMVP  CRBU  FIXX  DTIL  BEAM  MNOV  ELYM  MOLN  CSBR  CYT  ANEB  RZLT  HCWB 

Automate Your Wheel Strategy on NAUT

With Tiblio's Option Bot, you can configure your own wheel strategy including NAUT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NAUT
  • Rev/Share 0.0
  • Book/Share 1.5565
  • PB 0.4613
  • Debt/Equity 0.1509
  • CurrentRatio 17.3616
  • ROIC -0.3517

 

  • MktCap 90574264.0
  • FreeCF/Share -0.4684
  • PFCF -1.548
  • PE -1.3063
  • Debt/Assets 0.1289
  • DivYield 0
  • ROE -0.3187

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade NAUT Goldman Neutral Sell -- $1.75 Dec. 5, 2024

News

About Nautilus Biotechnology, Inc. (NAUT)

  • IPO Date 2020-08-07
  • Website https://www.nautilus.bio
  • Industry Biotechnology
  • CEO Sujal M. Patel
  • Employees 134
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.